NextFin News - Partners Group is nearing a deal for Aroma-Zone that could value the French beauty and wellness brand at close to €2 billion, a price that would place a fast-growing consumer asset among Europe’s more expensive private-market beauty transactions. The reported deal is still short of closing, but the valuation alone signals how aggressively buyers continue to pay for brands that can keep adding customers while broadening from niche ingredients into higher-frequency beauty products.
The numbers behind Aroma-Zone explain why the asset has stayed in play. The company said revenue rose 52% in 2025, after increases of 56% in 2024 and 42% in 2023. It sold 52 million products last year and had 4.5 million customers, up from 3 million in 2024. More than 90% of sales now come from ready-to-use products and dietary supplements, a change that has pushed the business beyond its original DIY roots and into a wider beauty-and-wellness franchise.
The process also has a clear ownership backstory. Eurazeo and Partners Group invested €414 million in Aroma-Zone in 2021, and the company said the founding family retained a significant stake. At that point, Aroma-Zone employed more than 350 people, operated seven stores across France and sold more than 1,900 products built around 3,000 recipes. The current process suggests that the company’s operating scale and category reach have grown enough to attract a much richer price.
What is less clear is whether that price reflects a structural re-rating or a cyclical peak in demand for premium consumer assets. Aroma-Zone has clearly expanded quickly, but private-market valuations often peak when investors extrapolate a hot growth phase too far into the future. The reported €2 billion number is therefore not just a takeout price; it is a test of whether a beauty brand can keep converting rapid growth into durable cash-generation power.
Why Aroma-Zone Has Become Such A Valuable Asset
Aroma-Zone is attractive because it is not behaving like a tired legacy cosmetics company. Its revenue growth has remained unusually high for three straight years, rising 42% in 2023, 56% in 2024 and 52% in 2025. The company sold 52 million products in 2025 and expanded its customer base from 3 million to 4.5 million in a single year. That combination points to a business that is still broadening reach, not merely squeezing more value out of the same audience.
The product mix shift is the more important strategic change. A business built around raw ingredients and DIY cosmetics usually carries a narrower user base and a lower-frequency purchase pattern. A business that gets more than 90% of sales from ready-to-use products and supplements has a different economics profile: more repeat consumption, easier mainstream retail penetration and a broader route to scale. That makes the company easier to underwrite as a consumer platform rather than a specialist niche.
The ownership structure helps explain why a sale could happen now. Eurazeo and Partners Group were already on the cap table after the 2021 investment, so the market is not comparing this to a fresh startup rerating. It is comparing an already scaled brand against a much higher valuation range built on more customers, a broader product mix and stronger brand recognition. If the buyer believes the company can keep extending its share gains, the purchase price starts to look like a payment for a longer runway rather than a premium for one good year.
That said, the valuation is only partly about company-specific execution. The private-equity market has continued to favor consumer brands with direct customer relationships, recurring demand and low industrial capital intensity. Beauty and wellness fit that template because they can combine pricing power with repeat purchases, and Aroma-Zone sits neatly inside that preference set. The asset is valuable not only because it is growing, but because it is growing in a category buyers still consider structurally attractive.
Even so, the danger is obvious: a valuation that looks sensible at 50%-plus revenue growth can look stretched if growth normalizes. A sponsor paying near €2 billion is assuming that current momentum can translate into a larger and more durable earnings base. If the growth profile cools before the customer and product mix gains fully embed, the same price will later read as a late-cycle bid for a hot consumer story.
What The Price Is Really Saying
A reported valuation near €2 billion is not just a statement about Aroma-Zone’s current revenue. It is a statement about how much future earnings power investors think is hiding behind the current numbers. The key mechanism is simple: more customers, a broader product mix and better channel penetration can lift lifetime value per customer, which supports a higher multiple even if headline revenue growth eventually slows. That is the real asset being priced here.
This is where the story becomes more structural than cyclical. Cyclical consumer strength can lift a business for a period, but structural change shows up in the architecture of demand. Aroma-Zone has moved from DIY ingredients toward ready-to-use products and supplements, and it says the latter now account for more than 90% of sales. That is not a temporary inventory swing. It is a different commercial model, one that can support broader distribution, higher repeat rates and a more mainstream brand position.
The second-order implication is that a rich takeout price can reshape how the market thinks about beauty assets more generally. If a sponsor is willing to pay close to €2 billion for a company whose recent growth is still running in the 50% range, then comparable consumer brands with visible customer growth and expanding assortments may also remain in demand. The transaction therefore tells you something about pricing discipline across the sector, not just about one target.
There is still a serious counter-thesis. Beauty and wellness are full of brands that looked structurally different during periods of fast growth and then saw valuations compress when category growth cooled, competition intensified or customer acquisition costs rose. The bearish case is that the current valuation assumes both continued share gains and smooth scaling into a more premium product mix, when the company may in fact face tougher retail competition, slower repeat conversion or a normalization in discretionary spending. In that scenario, €2 billion would be less a mark of permanent franchise quality and more a sign that buyers are still paying peak multiples for growth.
“We are gaining market share from pharmacies, parapharmacies, independent players and major beauty retailers as well,” Sabrina Herlory Rouget, Aroma-Zone’s chief executive, said in a recent company update.
The falsifying signal is specific: if revenue growth falls sharply from the 50%-plus range and customer gains slow materially at the same time, the structural-growth case weakens. A brand can enjoy a strong cycle and still deserve a premium, but it cannot keep commanding top-tier private-market pricing once the evidence of share gain stops showing up in the data. That is the metric that will matter more than the headline valuation.
What Happens Next
In the short term, a deal near the reported valuation would reinforce the idea that buyers still pay up for consumer brands with direct customer access, recurring demand and visible growth. That matters for the broader beauty and wellness market because it supports the pricing of comparable assets that also combine brand strength with product breadth.
Over the medium term, the main question is whether Aroma-Zone can keep turning product expansion into steadier earnings power. If customer growth, assortment expansion and mainstream channel penetration continue, the reported price could prove justified or even conservative. If growth cools and the product mix stops improving, the same valuation will begin to look like a peak-cycle entry point.
Longer term, the deal is really a test of whether growth itself still deserves a premium when it comes from a brand with a more durable operating model. The distinction between a platform and a passing momentum story is whether the customer base, the product mix and the revenue curve keep moving together. Aroma-Zone is being priced as if they will.
That is the real takeaway: the market is not just valuing Aroma-Zone’s sales trajectory. It is pricing the possibility that its growth has become a franchise, and franchises are what private buyers still pay the most to own.
Explore more exclusive insights at nextfin.ai.
